Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Buy recommendation.
Analyst Price Forecast Suggests 77.74% Upside
As of August 31, 2023, the average one-year price target for Ardelyx is 8.59. The forecasts range from a low of 6.06 to a high of $12.60. The average price target represents an increase of 77.74% from its latest reported closing price of 4.83.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ardelyx is 67MM, a decrease of 19.35%. The projected annual non-GAAP EPS is -0.44.
What is the Fund Sentiment?
There are 244 funds or institutions reporting positions in Ardelyx. This is an increase of 59 owner(s) or 31.89% in the last quarter. Average portfolio weight of all funds dedicated to ARDX is 0.08%, a decrease of 35.79%. Total shares owned by institutions increased in the last three months by 13.77% to 137,972K shares. 
The put/call ratio of ARDX is 0.35, indicating a bullish outlook.
What are Other Shareholders Doing?
Janus Henderson Group holds 21,827K shares representing 10.02% ownership of the company. In it's prior filing, the firm reported owning 22,112K shares, representing a decrease of 1.31%. The firm decreased its portfolio allocation in ARDX by 35.13% over the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 18,013K shares representing 8.27% ownership of the company. In it's prior filing, the firm reported owning 14,356K shares, representing an increase of 20.30%. The firm decreased its portfolio allocation in ARDX by 11.61% over the last quarter.
Millennium Management holds 6,976K shares representing 3.20% ownership of the company. In it's prior filing, the firm reported owning 11,020K shares, representing a decrease of 57.96%. The firm decreased its portfolio allocation in ARDX by 61.47% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 6,867K shares representing 3.15% ownership of the company. In it's prior filing, the firm reported owning 5,447K shares, representing an increase of 20.68%. The firm decreased its portfolio allocation in ARDX by 17.68% over the last quarter.
JAGLX - Janus Henderson Global Life Sciences Fund Class T holds 4,903K shares representing 2.25% ownership of the company. In it's prior filing, the firm reported owning 4,866K shares, representing an increase of 0.75%. The firm decreased its portfolio allocation in ARDX by 31.67% over the last quarter.
Ardelyx Background Information
(This description is provided by the company.)
Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
